Author

L. Y. hwa

Observed name: Lisa Hwa

Institution: Mayo Clinic

Observed institution: Mayo Clinic

OpenAlex ID: A5066886706

Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma

2025 · Kenneth J. C. Lim, Melinda Tan, et al. · Blood Cancer Journal · 19

Management of hematological toxicities after BCMA-directed CAR-T cell therapy

2026 · Joselle Cook, Supriya Gupta, et al. · Blood Cancer Journal · 4

Investigating the Role of Dexamethasone Prophylaxis for the Risk Reduction of Immune Effector Cell Delayed Neurotoxicity in Cilta-Cel Treated Patients

2026 · Kenneth Jin Chang Lim, Ricardo Daniel Parrondo, et al. · Transplantation and Cellular Therapy · 2

P966: Daratumumab, Carfilzomib, Pomalidomide and Elotuzumab for the Treatment of Poems Syndrome- the Mayo Clinic Experience

2022 · I. Vaxman, S. Kumar, et al. · HemaSphere · 2

Real-World Outcomes and Risk Factors in Multiple Myeloma Pts Receiving Cilta-Cel Including Functional High-Risk Status

2026 · Kenneth Jin Chang Lim, Ricardo Daniel Parrondo, et al. · Transplantation and Cellular Therapy

Works count: 5

Citation count: 27

H-index: 2

I10-index: 1